ClinicalTrials.gg
CompletedNCT06420089VIPER101Updated Nov 18, 2026

CD5-deleted Chimeric Antigen Receptor Cells (Senza5 CART5) for T Cell Non-Hodgkin Lymphoma (NHL)

A Phase 1 interventional study of Senza5 CART5 in T Cell Non-Hodgkin Lymphoma, sponsored by Vittoria Biotherapeutics. Completed at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Vittoria Biotherapeutics · Phase 1, Interventional, and Treatment

How we know

Updated Nov 18, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
19
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 173 studies in Lymphoma, T-Cell with a site in United States — 34 open to participants now, 50 under way, 2 of them phase 3. Lymphoma, T-Cell · United States.

Enrollment
115th of 166
19 · median 33
Started
2024
with 7 others
Phase 1
69 of 173
11 open now
Registered
155th of 173
by date

Among the 173 studies in Lymphoma, T-Cell with a site in United States, this one is the 115th largest by enrollment of the 166 interventional ones that give a count, is one of 8 that started in 2024, is one of 69 in phase 1, and was the 155th registered.

Lymphoma, T-Cell

310 studies on the registry are indexed under Lymphoma, T-Cell; 76 are open to participants now.

Browse Lymphoma, T-Cell studies →

Open to participants now

34 of the 173 studies in Lymphoma, T-Cell with a site in United States are open now. Recruiting first, the newest first:

29 more — sign in →

All 34 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 66 Lymphoma, T-Cell studies recruiting now, 40 (61%) set no upper age limit and 20 (30%) stop at 75 or younger; 14 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 173 studies in Lymphoma, T-Cell with a site in United States, or all of them as a file.
02

Study summary

This is an open-label phase I study to determine the safety and recommended phase 2 dose (RP2D) of Senza5 CART5 cells in patients with relapsed or refractory CD5 positive nodal T cell NHL. RP2D will be based on the safety, tolerability, pharmacokinetics, and preliminary efficacy of Senza5 CART5 cells. This trial will evaluate up to 5 dose levels using the Bayesian Optimal Interval (BOIN) design enrolling 3 patients in each cohort to assess safety and achieve therapeutic levels so that the RP2D of Senza5 CART5 cells given as a single IV infusion can be determined.

03

Conditions studied

  • T Cell Non-Hodgkin Lymphoma

Keywords

  • T Cell Lymphoma
  • Lymphoma
  • CD5KO CART5
  • Senza5 CART
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. or cytologically confirmed (r/r) CD5-positive nodal peripheral T-cell lymphoma (such as peripheral T-cell lymphoma-not otherwise specified (PTCL-NOS), nodal T-cell lymphomas with T-follicular helper (TFH) phenotype, including follicular T cell lymphoma, angioimmunoblastic lymphoma, or anaplastic large cell lymphoma) or other non-leukemic CD5+ aggressive mature T cell lymphomas (such as enteropathy-associated T cell lymphoma, monomorphic epitheliotropic intestinal T cell lymphoma, transformed mycosis fungoides, primary cutaneous aggressive epidermotropic CD8+ cytotoxic T-cell lymphoma, primary cutaneous insert gamma delta symbols lymphoma, or subcutaneous panniculitis like T cell lymphoma).
  2. ≥50% expression of CD5 on flow cytometry or IHC on malignant cells on the most recent
  3. Must have received at least one line of prior systemic therapy for their lymphoma; participants with anaplastic large cell lymphoma (ALCL) must have received prior brentuximab unless there was a to brentuximab.
  4. Evaluable disease defined by at least one lesion that can be measured in least 1 dimension and measures at least 1.5 cm in its longest dimension by CT or PET scan, or bone/bone marrow involvement, or skin involvement.
  5. No circulating CD5+ malignant cells identified by peripheral blood flow cytometry must be present.

Exclusion criteria

Exclusion Criteria:

  1. Pregnant or lactating (nursing) women.
  2. infection.
  3. Concurrent use of systemic or medications.
  4. Any uncontrolled active medical disorder that would preclude participation as outlined.
  5. History of immunodeficiency.
  6. History of prior chimeric antigen receptor therapy (CAR T), autologous or syngeneic HCT \<100 days from transplant at the time of cell infusion or previous allo-HCT.
  7. Active and/or systemic inflammatory or diseases.
  8. Signs or symptoms indicative of active CNS involvement.
  9. Known history or prior diagnosis of optic neuritis or other immunologic or inflammatory disease affecting the central nervous system, and unrelated to lymphoma or previous lymphoma treatment.
  10. Clinically apparent arrhythmia, or arrhythmias that are not stable on medical management
  11. Current participation in or prior participation in a study of an agent or using an investigational device within 2 weeks of the first dose of treatment.
  12. Prior monoclonal antibody therapy within 4 weeks prior to study Day 1
  13. Prior use of alemtuzumab
  14. Prior chemotherapy targeted small molecule therapy, or radiation therapy within 2 weeks prior to study Day 1
  15. Uncontrolled active infection requiring systemic therapy.
  16. Circulating CD5+ malignant cells identified by peripheral blood flow cytometry present.
  17. Active and/or systemic inflammatory or autoimmune diseases.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
19 participants (actual)

Study arms

  • Experimental
    Senza5 CART5 with standard of care lymphodepletion

    Four treatment arms with Standard of Care Lymphodepletion: Fludarabine 25mg/m2 IV for 3 days Cyclophosphamide 250mg/m2 IV for 3 days

    Drug: Senza5 CART5

  • Experimental
    Senza5 CART5 without standard of care lymphodepletion

    Four treatment arms in patients are lymphopenic into the corresponding dose level.

    Drug: Senza5 CART5

Interventions

  • DrugSenza5 CART5

    The Senza5 CART5 drug product consists of a dual population of engineered autologous T cells: CD5 knockout (KO)cells and CD5KO-CART5 cells

06

What researchers measure

Primary outcomes

  1. Determine the recommended phase 2 dose (RP2D) of Senza5 CART5 cells

    Measure the occurrence of Dose Limiting Toxicity events of each dose level per arm

    Time frame: 12 months

Secondary outcomes

  1. Determine the safety of Senza5 CART5 cells

    Quantify quantifying the type and frequency of adverse events

    Time frame: 12 months

  2. Determine the maximum tolerated dose (MTD)

    Quantify the safety and tolerability of the highest dose

    Time frame: 12 months

  3. Determine the manufacturing feasibility of Senza5 CART5

    Quantify the number of product release failures and occurrence of dose failures (inability to meet targeted dose)

    Time frame: 12 months

  4. Determine efficacy of Senza5 CART5

    Measure the objective response rate

    Time frame: 12 months

  5. Determine efficacy of Senza5 CART5

    Measure the complete response rate

    Time frame: 12 months

  6. Determine efficacy of Senza5 CART5

    Measure the best overall response

    Time frame: 12 months

  7. Determine efficacy of Senza5 CART5

    Measure the duration of response

    Time frame: 12 months

  8. Determine efficacy of Senza5 CART5

    Measure the overall survival

    Time frame: 12 months

  9. Determine efficacy of Senza5 CART5

    Measure the progression free survival

    Time frame: 12 months

07

Study locations

2 sites
  • Columbia University Irving Medical Center
    New York, New York 10032, United States
  • University of Pennsylvania - Abramson Caner Center
    Philadelphia, Pennsylvania 19104, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2024 to primary completion in Sep 2026, 23 months.

Of 59 phase 1 interventional studies under Lymphoma, T-Cell, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 75. This study's 23 months is below that.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 18, 2026: primary completion Aug 2028 → Sep 2026 and completion Aug 2029 → Sep 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 30, 2024
First posted
May 17, 2024
StartActual
Oct 4, 2024
Primary completionActual
Sep 24, 2026was Aug 2028
CompletionActual
Sep 24, 2026was Aug 2029
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Nov 18, 2026
Primary completion
Aug 30, 2028→Sep 24, 2026 (actual)
Nov 18, 2026
Study completion
Aug 30, 2029→Sep 24, 2026 (actual)
Nov 18, 2026
Enrollment
30 (estimated)→19 (actual)
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    Recruiting→Completed
    Primary completion Aug 30, 2028→Sep 24, 2026 (now actual)
    Study completion Aug 30, 2029→Sep 24, 2026 (now actual)
    Enrollment 30 (estimated)→19 (actual)
    + 3 other changes: verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06420089
Lead sponsor
Vittoria Biotherapeutics
Responsible party
Sponsor
First posted
May 17, 2024
Start date
Oct 4, 2024
Primary completion
Sep 24, 2026
Completion
Sep 24, 2026
Last update
Nov 18, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion